You have requested access to member only content.
Focusing on adverse drug events is still crucial during the COVID-19 pandemic
The nation’s hospitals continue to grapple with COVID-19, a pandemic that has strained staff and resources like never before. But even amid this ongoing public health emergency, it’s important to not forget—and to continue addressing—patient safety concerns that impact outcomes and costs.
Foremost among patient safety issues are adverse drug events (ADE), which are responsible for 100,000 deaths every year and (before COVID-19) were estimated to be the fourth leading cause of death in the United States. ADEs impact 2 million hospital stays annually in the U.S. and prolong inpatient hospital stays by 1.7 to 4.6 days.
Despite efforts to reduce adverse drug events and improve patient safety—including the Centers for Medicare & Medicaid Services’ (CMS) in-depth undertaking to create policies, value-based purchasing programs, and other financial incentives aimed at preventing hospital ADEs—the problem perseveres. The result is an increase of about $136 billion in annual U.S. healthcare costs, much of which could be avoided.
This is an excerpt from members-only content. Please log in or become a member to access the full content.
Please Log InForgot username or password?
Not a member? Let's fix that!
A membership to Accreditation and Quality Compliance Center provides accreditation and safety professionals with a collection of continuously updated tools, best-practice strategies, and compliance tips developed by industry experts. With two membership options, you can customize your access level depending on your education and training needs.
Register to access the free content available on the site or become a member today. Click here for more information.
For questions and support, please call customer service: 1-800-650-6787.